IntegruAB signed a memorandum of understanding with Garwood Medical Devices, LLC. The intent is to explore a collaboration aimed at expanding treatment indications for the OPRAT Implant System. Integrum Founder and Chairman, Dr. Rickard Brånemark, and Garwood President/CEO Wayne Bacon, announced the intent to conduct joint research activities on the use of Garwood's BioPraxT technology in relation to Integrum's bone-anchored prostheses system for amputees. The OPRAT Implant System has been used in more than 500 surgeries, including those taking place at Walter Reed Hospital, in the treatment of many U.S. military veterans who became injured in combat. This innovative method, which is based on osseointegration - through which the prostheses are directly attached to the bone - provides a beneficial alternative to the traditional socket prosthesis. Dr. Brånemark, in his capacity as an individual, is also an investor in Garwood Medical Devices, LLC. As with any implant, infections can occur. Although rare, these infections can be devastating to the patient and costly for the overall health care system, with few effective treatment options. Garwood Medical's BioPraxT device is under investigation to study the elimination of biofilm infections on prosthetic knee implants during early intervention procedures and used alongside the current standard of care. It is currently in pre-clinical trials at the University at Buffalo'sJacobs School of Medicine. BioPraxT was accepted into the FDA's Breakthrough Device Program in October 2019, an important milestone on the path to market acceptance.